Patients’ characteristics in the longitudinal cohort
| Characteristics . | All patients (N = 37) . | No relapse (n = 25) . | Relapse (n = 12) . | P . |
|---|---|---|---|---|
| Age at transplant, y | 51.5 [35.4-61.2] | 47.0 [33.9-60.0] | 54.0 [37.7-62.8] | .40 |
| Sex | .99 | |||
| Female | 17 (46) | 12 (48) | 5 (42) | |
| Male | 20 (54) | 13 (52) | 7 (58) | |
| Diagnosis | .12 | |||
| AML | 26 (70) | 20 (80) | 6 (50) | |
| MDS | 11 (30) | 5 (20) | 6 (50) | |
| ELN classification (AML) | .74 | |||
| Favorable | 7 (27) | 6 (30) | 1 (17) | |
| Intermediate | 10 (38) | 8 (40) | 2 (33) | |
| Adverse | 9 (35) | 6 (30) | 3 (50) | |
| Number of pre-transplant treatment | .73 | |||
| 0 | 2 (5) | 2 (8) | 0 (0) | |
| 1 | 23 (62) | 14 (56) | 9 (75) | |
| ≥2 | 12 (32) | 9 (36) | 3 (25) | |
| Disease status at transplant | .11 | |||
| CR1 | 17 (46) | 13 (52) | 4 (33) | |
| CR ≥ 2 | 10 (27) | 8 (32) | 2 (17) | |
| No CR | 10 (27) | 4 (16) | 6 (50) | |
| Conditioning | .01 | |||
| Myeloablative | 14 (38) | 13 (52) | 1 (8) | |
| Reduced intensity | 22 (59) | 12 (48) | 10 (83) | |
| Sequential | 1 (3) | 0 (0) | 1 (8) | |
| Serotherapy | 20 (54) | 12 (48) | 8 (67) | .32 |
| Donor | .58 | |||
| Related | 18 (49) | 11 (44) | 7 (58) | |
| Matched unrelated | 16 (43) | 11 (44) | 5 (42) | |
| Mismatched unrelated | 3 (8) | 3 (12) | 0 (0) | |
| Stem cells source | .11 | |||
| Bone marrow | 1 (3) | 1 (4) | 0 (0) | |
| Peripheral blood | 34 (92) | 24 (96) | 10 (83) | |
| Umbilical cord blood | 2 (5) | 0 (0) | 2 (17) | |
| GVHD prophylaxis | .12 | |||
| CSA | 1 (3) | 1 (4) | 0 (0) | |
| CSA + MMF | 19 (51) | 10 (40) | 9 (75) | |
| CSA + MTX | 17 (46) | 14 (56) | 3 (25) | |
| Acute GVHD all grades | 18 (49) | 15 (60) | 3 (25) | .08 |
| Acute GVHD grade III/IV | 3 (8) | 3 (12) | 0 (0) | .54 |
| Chronic GVHD | 10 (27) | 9 (36) | 1 (8) | .12 |
| None | 3 (30) | 3 (33) | 0 (0) | |
| Moderate | 5 (50) | 4 (44) | 1 (100) | |
| Extensive | 2 (20) | 2 (22) | 0 (0) | |
| CMV reactivation | 6 (16) | 4 (16) | 2 (17) | .99 |
| Death | 8 (22) | 1 (4) | 7 (58) | .0005 |
| Cause of death | ||||
| GVHD | 1 (13) | 1 (4) | 0 (0) | .0005 |
| Relapse | 7 (87) | 0 (0) | 7 (58) |
| Characteristics . | All patients (N = 37) . | No relapse (n = 25) . | Relapse (n = 12) . | P . |
|---|---|---|---|---|
| Age at transplant, y | 51.5 [35.4-61.2] | 47.0 [33.9-60.0] | 54.0 [37.7-62.8] | .40 |
| Sex | .99 | |||
| Female | 17 (46) | 12 (48) | 5 (42) | |
| Male | 20 (54) | 13 (52) | 7 (58) | |
| Diagnosis | .12 | |||
| AML | 26 (70) | 20 (80) | 6 (50) | |
| MDS | 11 (30) | 5 (20) | 6 (50) | |
| ELN classification (AML) | .74 | |||
| Favorable | 7 (27) | 6 (30) | 1 (17) | |
| Intermediate | 10 (38) | 8 (40) | 2 (33) | |
| Adverse | 9 (35) | 6 (30) | 3 (50) | |
| Number of pre-transplant treatment | .73 | |||
| 0 | 2 (5) | 2 (8) | 0 (0) | |
| 1 | 23 (62) | 14 (56) | 9 (75) | |
| ≥2 | 12 (32) | 9 (36) | 3 (25) | |
| Disease status at transplant | .11 | |||
| CR1 | 17 (46) | 13 (52) | 4 (33) | |
| CR ≥ 2 | 10 (27) | 8 (32) | 2 (17) | |
| No CR | 10 (27) | 4 (16) | 6 (50) | |
| Conditioning | .01 | |||
| Myeloablative | 14 (38) | 13 (52) | 1 (8) | |
| Reduced intensity | 22 (59) | 12 (48) | 10 (83) | |
| Sequential | 1 (3) | 0 (0) | 1 (8) | |
| Serotherapy | 20 (54) | 12 (48) | 8 (67) | .32 |
| Donor | .58 | |||
| Related | 18 (49) | 11 (44) | 7 (58) | |
| Matched unrelated | 16 (43) | 11 (44) | 5 (42) | |
| Mismatched unrelated | 3 (8) | 3 (12) | 0 (0) | |
| Stem cells source | .11 | |||
| Bone marrow | 1 (3) | 1 (4) | 0 (0) | |
| Peripheral blood | 34 (92) | 24 (96) | 10 (83) | |
| Umbilical cord blood | 2 (5) | 0 (0) | 2 (17) | |
| GVHD prophylaxis | .12 | |||
| CSA | 1 (3) | 1 (4) | 0 (0) | |
| CSA + MMF | 19 (51) | 10 (40) | 9 (75) | |
| CSA + MTX | 17 (46) | 14 (56) | 3 (25) | |
| Acute GVHD all grades | 18 (49) | 15 (60) | 3 (25) | .08 |
| Acute GVHD grade III/IV | 3 (8) | 3 (12) | 0 (0) | .54 |
| Chronic GVHD | 10 (27) | 9 (36) | 1 (8) | .12 |
| None | 3 (30) | 3 (33) | 0 (0) | |
| Moderate | 5 (50) | 4 (44) | 1 (100) | |
| Extensive | 2 (20) | 2 (22) | 0 (0) | |
| CMV reactivation | 6 (16) | 4 (16) | 2 (17) | .99 |
| Death | 8 (22) | 1 (4) | 7 (58) | .0005 |
| Cause of death | ||||
| GVHD | 1 (13) | 1 (4) | 0 (0) | .0005 |
| Relapse | 7 (87) | 0 (0) | 7 (58) |
Data are number of patients (percentage of study group) unless stated otherwise. Boldface indicates significant values.
AML, acute myeloid leukemia; CMV, cytomegalovirus; CR, complete response; CSA, cyclosporine; ELN, European LeukemiaNet; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX, methotrexate.